(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 99.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Crispr Therapeutics Ag's revenue in 2025 is $38,337,000.On average, 30 Wall Street analysts forecast CRSP's revenue for 2025 to be $2,825,842,509, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $12,834,082,378. On average, 30 Wall Street analysts forecast CRSP's revenue for 2026 to be $13,901,444,988, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $145,523,455,791.
In 2027, CRSP is forecast to generate $30,404,586,336 in revenue, with the lowest revenue forecast at $4,109,346,047 and the highest revenue forecast at $224,241,448,249.